{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:10:17Z","timestamp":1779289817164,"version":"3.51.4"},"reference-count":45,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"unspecified","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200644"],"award-info":[{"award-number":["82200644"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371756"],"award-info":[{"award-number":["82371756"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science Fund of Universities of Anhui Province for Distinguished Young Scholars","award":["2023AH020032"],"award-info":[{"award-number":["2023AH020032"]}]},{"DOI":"10.13039\/501100003995","name":"Anhui Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["2408085MH209"],"award-info":[{"award-number":["2408085MH209"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2026,5,4]]},"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy for patients with refractory or relapsed lymphoma or leukemia. However, inefficient activity and insufficient persistence of CAR T cells impede the durability of its therapeutic efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Kr\u00fcppel-like factor 4 (KLF4)-overexpressing CAR T cells were generated and assessed for function, exhaustion, and transcriptional changes using in vitro stimulation models and RNA sequencing, with antitumor efficacy validated in mouse models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We report that KLF4 overexpression enhances the durability of CAR T-cell antitumor efficacy. KLF4 overexpression enhanced CAR T-cell activity and promoted the differentiation into effector CAR T cells. Furthermore, KLF4 overexpression prevented CAR T-cell exhaustion induced by continuous tumor antigen stimulation. RNA sequencing data confirmed that KLF4 overexpression led to the upregulation of genes involved in effector functions and the downregulation of genes associated with exhaustion in CAR T cells. Notably, KLF4-overexpressing CAR T cells delayed tumor growth, prolonged the survival of mice with hematological malignancies, and exhibited reduced exhaustion and enhanced effector functions in vivo relative to normal CAR T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings highlight the potential of KLF4 overexpression as a therapeutic approach to counteract CAR T-cell exhaustion and enhance antitumor activity, underscoring its therapeutic promise in clinical immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-014691","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:15:30Z","timestamp":1779286530000},"page":"e014691","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["KLF4 overexpression in CAR T cells enhances antitumor potency by preventing exhaustion"],"prefix":"10.1136","volume":"14","author":[{"given":"Haoqi","family":"Wang","sequence":"first","affiliation":[{"name":"School of Pharmacy, Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianglong","family":"Meng","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital of USTC, Anhui Provincial Cancer Hospital, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anqi","family":"Su","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wentao","family":"Qin","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Shen","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunyu","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingling","family":"Gu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujie","family":"Ma","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaxing","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Mao","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongdong","family":"Ji","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Zong","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, the First Affiliated Hospital of Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meijuan","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, the First Affiliated Hospital of Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1824-8861","authenticated-orcid":false,"given":"Jingjing","family":"Cong","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Anhui Medical University, Hefei, China"},{"name":"Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7212-7156","authenticated-orcid":false,"given":"Xuefu","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Anhui Medical University, Hefei, China"},{"name":"Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Anhui Medical University, Hefei, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"2026052007151989000_14.5.e014691.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462"},{"key":"2026052007151989000_14.5.e014691.2","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0181"},{"key":"2026052007151989000_14.5.e014691.3","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026052007151989000_14.5.e014691.4","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-024-01639-1","article-title":"Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress","volume":"17","author":"Huang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2026052007151989000_14.5.e014691.5","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01663-0","article-title":"The journey of CAR-T therapy in hematological malignancies","volume":"21","author":"Lu","year":"2022","journal-title":"Mol Cancer"},{"key":"2026052007151989000_14.5.e014691.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101241"},{"key":"2026052007151989000_14.5.e014691.7","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01406-8","article-title":"CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting","volume":"16","author":"Huang","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2026052007151989000_14.5.e014691.8","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature New Biol"},{"key":"2026052007151989000_14.5.e014691.9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006959","article-title":"Patient-reported outcomes in CD30-directed CAR-T cells against relapsed\/refractory CD30+ lymphomas","volume":"11","author":"Tschernia","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026052007151989000_14.5.e014691.10","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.cmet.2025.04.008","article-title":"Foxp3 confers long-term efficacy of chimeric antigen receptor-T cells via metabolic reprogramming","volume":"37","author":"Niu","year":"2025","journal-title":"Cell Metab"},{"key":"2026052007151989000_14.5.e014691.11","doi-asserted-by":"crossref","unstructured":"Zhou Y , Zhao W , Zhu Y , et al . CXCL13 Expression Promotes CAR T Cell Antitumor Activity and Potentiates Response to PD\u20101 Blockade. Adv Sci (Weinh) 2025;12. doi:10.1002\/advs.202508095","DOI":"10.1002\/advs.202508095"},{"key":"2026052007151989000_14.5.e014691.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0221-9"},{"key":"2026052007151989000_14.5.e014691.13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-012017-043208"},{"key":"2026052007151989000_14.5.e014691.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1"},{"key":"2026052007151989000_14.5.e014691.15","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02079-8","article-title":"Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy","volume":"23","author":"Xia","year":"2024","journal-title":"Mol Cancer"},{"key":"2026052007151989000_14.5.e014691.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.09.006"},{"key":"2026052007151989000_14.5.e014691.17","doi-asserted-by":"publisher","DOI":"10.1038\/nri3862"},{"key":"2026052007151989000_14.5.e014691.18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature New Biol"},{"key":"2026052007151989000_14.5.e014691.19","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-019-0985-x","article-title":"NR4A transcription factors limit CAR T cell function in solid tumours","volume":"567","author":"Chen","year":"2019","journal-title":"Nature New Biol"},{"key":"2026052007151989000_14.5.e014691.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.09.013"},{"key":"2026052007151989000_14.5.e014691.21","doi-asserted-by":"crossref","first-page":"6195","DOI":"10.1016\/j.ymthe.2025.09.006","article-title":"TOX-induced lnc-SUMF2-8 compromises antitumor function and anti-PD-1 response of CD8+ T cells via lysosome-dependent degradation of TCF-1","volume":"33","author":"Jiang","year":"2025","journal-title":"Mol Ther"},{"key":"2026052007151989000_14.5.e014691.22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008665","article-title":"NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors","volume":"12","author":"Nakagawara","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026052007151989000_14.5.e014691.23","doi-asserted-by":"crossref","DOI":"10.1126\/science.adn2337","article-title":"KLF2 maintains lineage fidelity and suppresses CD8 T cell exhaustion during acute LCMV infection","volume":"387","author":"Fagerberg","year":"2025","journal-title":"Science"},{"key":"2026052007151989000_14.5.e014691.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01685-w"},{"key":"2026052007151989000_14.5.e014691.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00964-8"},{"key":"2026052007151989000_14.5.e014691.26","doi-asserted-by":"publisher","DOI":"10.1096\/fj.11-186924"},{"key":"2026052007151989000_14.5.e014691.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2013.09.008"},{"key":"2026052007151989000_14.5.e014691.28","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adc9346","article-title":"Kr\u00fcppel-like factor 4 regulates the cytolytic effector function of exhausted CD8 T cells","volume":"8","author":"Nah","year":"2022","journal-title":"Sci Adv"},{"key":"2026052007151989000_14.5.e014691.29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849"},{"key":"2026052007151989000_14.5.e014691.30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature New Biol"},{"key":"2026052007151989000_14.5.e014691.31","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adw7685","article-title":"Modulating AP-1 enables CAR T cells to establish an intratumoral stemlike reservoir and overcomes resistance to PD-1 blockade","volume":"11","author":"Snyder","year":"2026","journal-title":"Sci Immunol"},{"key":"2026052007151989000_14.5.e014691.32","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838"},{"key":"2026052007151989000_14.5.e014691.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01896-9"},{"key":"2026052007151989000_14.5.e014691.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.06.012"},{"key":"2026052007151989000_14.5.e014691.35","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adp9371","article-title":"TET2 regulates early and late transitions in exhausted CD8+ T cell differentiation and limits CAR T cell function","volume":"10","author":"Dimitri","year":"2024","journal-title":"Sci Adv"},{"key":"2026052007151989000_14.5.e014691.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0311-z"},{"key":"2026052007151989000_14.5.e014691.37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009827","article-title":"Differential regulation of calcium-NFAT signaling pathway by Akt isoforms: unraveling effector dynamics and exhaustion of cytotoxic T lymphocytes in tumor microenvironment","volume":"13","author":"Chen","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026052007151989000_14.5.e014691.38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15419061.2018.1444034","article-title":"Kr\u00fcppel-like factor 4 mediates cellular migration and invasion by altering RhoA activity","volume":"24","author":"Brauer","year":"2018","journal-title":"Cell Commun Adhes"},{"key":"2026052007151989000_14.5.e014691.39","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-015-0373-6","article-title":"Impaired autophagy in mouse embryonic fibroblasts null for Kr\u00fcppel-like Factor 4 promotes DNA damage and increases apoptosis upon serum starvation","volume":"14","author":"Liu","year":"2015","journal-title":"Mol Cancer"},{"key":"2026052007151989000_14.5.e014691.40","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14058","article-title":"Klf4, Klf2, and Zfp148 activate autophagy-related genes in smooth muscle cells during aortic aneurysm formation","volume":"7","author":"Salmon","year":"2019","journal-title":"Physiol Rep"},{"key":"2026052007151989000_14.5.e014691.41","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14003","article-title":"K48-linked KLF4 ubiquitination by E3 ligase Mule controls T-cell proliferation and cell cycle progression","volume":"8","author":"Hao","year":"2017","journal-title":"Nat Commun"},{"key":"2026052007151989000_14.5.e014691.42","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41392-024-01986-y","article-title":"MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB","volume":"9","author":"Wang","year":"2024","journal-title":"Sig Transduct Target Ther"},{"key":"2026052007151989000_14.5.e014691.43","doi-asserted-by":"crossref","first-page":"151061","DOI":"10.1016\/j.ejcb.2019.151061","article-title":"Cells deficient for Kr\u00fcppel-like factor 4 exhibit mitochondrial dysfunction and impaired mitophagy","volume":"99","author":"Rosencrans","year":"2020","journal-title":"Eur J Cell Biol"},{"key":"2026052007151989000_14.5.e014691.44","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA117.001323"},{"key":"2026052007151989000_14.5.e014691.45","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.stemcr.2017.01.026","article-title":"A Role for KLF4 in Promoting the Metabolic Shift via TCL1 during Induced Pluripotent Stem Cell Generation","volume":"8","author":"Nishimura","year":"2017","journal-title":"Stem Cell Reports"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-014691","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:15:36Z","timestamp":1779286536000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-014691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5,20]]},"published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1136\/jitc-2025-014691"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-014691","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]}}}